Description of Invention:
Tissue regeneration and tumorigenesis are complex, adaptive processes controlled by cues from the host and from the tissue microenvironment. A variety of signals orchestrate the response to injury that results in regeneration and repair of a wound. Both tissue regeneration and carcinogenesis involve cell proliferation, survival, and migration that are controlled by growth factors and cytokines as well as inflammatory and angiogenic signals. Thus, wounds and cancers share a number of phenotypic similarities in cellular behavior, signaling molecules, and gene expression.
The inventors have compared global gene expression data from a model of renal regeneration and repair (RRR) with gene expression in renal cell carcinoma (RCC), and asked whether those two processes do, in fact, share molecular features and regulatory mechanisms. The majority (77%) of the genes expressed in RRR and RCC were concordantly regulated, whereas only 23% were discordant (i.e., changed in opposite directions). Thus, the genes regulated in the discordant direction provides diagnostic and therapeutic biomarkers to target RCC and not the normal regenerating tissue (kidney wound healing), as well as treating renal ischemia without promoting RCC.
Applications:
Biomarkers for immunotherapy, drug targeting and drug screening, for targeting tumors and not normal regenerating tissue
Biomarkers for immunotherapy, drug targeting and drug screening, for targeting ischemic tissue and not tumors
Method to determine and monitor renal tissue health status
Method to accurately diagnose and treat RCC
Method for improving renal ischemia recovery without promoting RCC
RCC biomarker inhibitors such as siRNA
Advantages:
Rapid and accurate diagnostic for RCC and monitoring renal tissue health
Market:
RCC is one of the top ten most prevalent cancers in the U.S. and it accounts for 12,500 deaths annually. Approximately 36,000 new cases of RCC are diagnosed annually.
The rate of 5-year survival varies by stage: 66% for stage I, 64% for stage II, 42% for stage III, and 11% for stage IV.
Cancer is the therapeutic area of highest potential, with an annual market value expected to be in excess of US 40 billion dollars in 2020.
Development Status:
The technology is currently in the pre-clinical stage of development.
Inventors:
Joseph Riss (NCI) et al.
Patent Status:
DHHS Reference No. E-064-2005/0 --
U.S. Provisional Application No. 60/649,208 filed 01 Feb 2005
PCT Application No. PCT/US2006/003611 filed 01 Feb 2006
U.S. Patent Application No. 11/883,535 filed 31 Jul 2007
J Riss et al. Cancers as wounds that do not heal: differences and similarities between renal regeneration/repair and renal cell carcinoma. Cancer Res. 2006 July 15;66(14):7216-7224. [PubMed abs]
C Phillips. Study Strengthens Argument of Cancer as "Wounds that Do Not Heal". NCI Cancer Bulletin 2006 July 25;3(30):1-2. [view article]
Licensing Status: Available for exclusive or non-exclusive licensing.
Collaborative Research Opportunity:
The National Cancer Institute, Center for Cancer Research, Laboratory of Cancer Biology and Genetics, Wound Healing and Oncogenesis (NCI/CCR/LCBG), is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize topics of invention or related to cancer biology, metastasis, wound healing, bioinformatics, pharmacogenomics and therapeutic. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.
Portfolios: Rare Diseases Miscellaneous Internal Medicine Cancer
Cancer -Diagnostics-In Vivo-Other Cancer -Therapeutics-Biological Response Modifiers-Growth Factors Cancer -Diagnostics Cancer -Therapeutics Internal Medicine-Therapeutics Miscellaneous-Miscellaneous
For Additional Information Please Contact: Jennifer Wong
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-4633
Email: wongje@mail.nih.gov
Fax: (301)402-0220
